- A team of neuroscientists and biologists from the University of Florida have discovered a novel gene therapy to reverse the degenerative effects of multiple sclerosis
- Adeno-associated virus (AAV) immunotherapy has immense potential for reversing the degenerative effects of multiple sclerosis
- This gene immune therapy leads to the production of MOG-specific regulatory T cells (Tregs) in the body and this restores the immune response of the body in multiple sclerosis
Immune-regulatory Gene Therapy for Multiple Sclerosis (MS)T-regulatory cells known as Tregs have a critical role in immune tolerance. Tregs suppress the effector CD4+ T cell subsets which control and mediate autoimmune responses. Suppression and dysregulation of CD4+CD25+FOXP3+ Tregs have been linked the pathogenesis of MS. A good therapy to control the disease is to selectively induce auto-antigen specific CD4+CD25+FOXP3+ (forkhead box P3) Tregs. There have been many studies indicating the potential of Treg-based immunotherapies. For example, the transfer of polyclonal CD4+ CD25+ Tregs has temporarily prevented or reduced the effects of autoimmune encephalomyelitis (EAE) in mouse models of MS. However, the challenge is to develop a robust and sustainable immune-regulatory therapy.
A research team from the University of Florida have discovered a novel gene therapy to reverse the degenerative effects of multiple sclerosis using adeno-associated virus (AAV) immunotherapy, which has immense potential for reversing the degenerative effects of multiple sclerosis. The research team developed an in-vivo gene therapy using pre-clinical mouse models. They designed a liver-targeting gene transfer vector which enables the expression of full-length myelin oligodendrocyte glycoprotein (MOG) in hepatocytes (liver cells). This gene immune therapy leads to the production of MOG-specific regulatory T cells (Tregs) in the body and this restores the immune response of the body in multiple sclerosis.
‘Adeno-associated virus (AAV) immunotherapy has immense potential for reversing the degenerative effects of multiple sclerosis.’
Concluding EvidenceFrom the above experiment and reporting, it is clear that AAV therapy plus a short course of immunosuppressant drug rapamycin not only prevents debilitating symptoms of MS but also reverses existing symptoms if administered in the early stages. This model of gene therapy in combination with an immunosuppressant is superior to traditional models of prophylactic treatment using non-specific drugs. This clinical therapy can not only be used for MS but has the potential for other human autoimmune diseases and this research needs further investigation on these lines.
What is Multiple Sclerosis?Multiple Sclerosis is an autoimmune disease of the central nervous system (CNS) affecting the brain and spinal cord. Myelin is a protective sheath around the nerve fibers in the CNS. The nerve fibers are responsible for transmitting messages between the brain and the body. In MS, the body's immune system mistakes the myelin for a foreign body and starts attacking the protective sheath. The damaged myelin sheath often leaves the nerve fibers exposed with lesions and plaques. The damaged myelin sheath can disrupt the flow of brain-body messages. In some cases, the nerve fibers can get damaged and this damage is what leads to increasing disability in MS.
Some of the early signs and symptoms of MS can include:
- Vision disturbances with conditions like optic neuritis
- Problems with balance, walking and giddiness or dizziness
- Muscle spasms and stiffness
- Problems with swallowing and speech
- Unexplained fatigue
- Memory and issues with cognition
- Frequent bouts of infections and inflammation
- Keeler et al., Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis, Molecular Therapy (2017), http://dx.doi.org/10.1016/j.ymthe.2017.09.001
- Danikowski, K. M., S. Jayaraman, and B. S. Prabhakar. "Regulatory T cells in multiple sclerosis and myasthenia gravis." Journal of Neuroinflammation 14, no. 1 (2017): 117. https://doi.org/10.1186/s12974-017-0892-8
- Multiple Sclerosis Society - (https://www.mssociety.org.uk/)
- << Parkinson's Disease Drug Carbidopa has Anticancer potential
- Anesthesia can Pose a Danger to Kids Younger Than Three >>